Cargando…
Exome sequencing reveals a potential mutational trajectory and treatments for a specific pancreatic cancer patient
Pancreatic cancer is the fourth biggest killer, and has one of the worst prognoses, of any cancer type. Approximately 95% of patients diagnosed with pancreatic cancer will not survive beyond 5 years post diagnosis, and these statistics have barely improved in over 40 years. Here, genomic changes in...
Autor principal: | Cotterell, James |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014375/ https://www.ncbi.nlm.nih.gov/pubmed/24833909 http://dx.doi.org/10.2147/OTT.S45232 |
Ejemplares similares
-
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms
por: Tenedini, E, et al.
Publicado: (2014) -
MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS
por: Pugh, Trevor J., et al.
Publicado: (2012) -
Identification of Key Genes Mutations Associated With the Radiosensitivity by Whole Exome Sequencing in Pancreatic Cancer
por: Hu, Bin, et al.
Publicado: (2021) -
Whole-Exome Sequencing Reveals Mutational Signature of Hypertrophic Cardiomyopathy
por: Wang, Xi-Qin, et al.
Publicado: (2023) -
Identification of Mutated Peptides in Bladder Cancer From Exomic Sequencing Data Reveals Negative Correlation Between Mutation-Specific Immunoreactivity and Inflammation
por: Wang, Chen, et al.
Publicado: (2020)